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The role of transcription factor activator protein-2b (AP-2b) in foam cell formation was investigated.
Uptake assay of DiI-labeled oxidized low density lipoprotein and the lipid quantitative analysis by
high performance liquid chromatography showed AP-2b promoted the lipid accumulation. The
quantitative real-time RT-PCR and Western blot indicated that AP-2b upregulated the expression
of CD36. Luciferase assay, electrophoretic mobility shift assay and chromatin immunoprecipitation
conﬁrmed that AP-2b bound to AP-2 binding sites in CD36 promoter region and enhanced the pro-
moter activity of CD36 gene. We conclude that AP-2b may function in foam cell formation through
enhancing the transcription and expression of CD36 followed by increased lipid uptake.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Activator protein-2 (AP-2) family proteins, consisting of ﬁve
homologous 52 kDa polypeptides of AP-2a, b, c, d and e, are impor-
tant transcription factors for the activation of a number of genes,
which play an important role in embryogenesis and tumorigenesis
[1]. Recent studies have reported that over-expression of activator
protein-2b (AP-2b) leads to lipid accumulation in 3T3-L1 adipo-
cytes [2]. However, it is not known whether AP-2b can enhance li-
pid accumulation in macrophages and the subsequent foam cell
formation.
Foam cells constitute the major cell components in atheroscle-
rotic lesions. As a member of the scavenger receptor gene family,
CD36 plays a very important role in atherogenesis by contributing
to lipid uptake and foam cell formation. This cell surface receptor
recognizes oxidized LDL (oxLDL) and mediates accumulation of
cholesteryl esters in macrophages to stimulate foam cell formation
[3,4]. Recently, transcriptional control of CD36 expression associ-
ated with atherosclerotic diseases has attracted the attention of
many medical researchers. Peroxisome proliferators activator
RE
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ucleotide; bp, base pair; h,receptor (PPAR) and nuclear factor-kappaB (NF-jB) have been
shown to mediate foam cell formation through regulating CD36
expression [5,6]. However, transcription factor AP-2b has not yet
been investigated on this regard.
This study investigates whether AP-2b induces macrophage-
derived foam cell formation and how AP-2b controls the transcrip-
tion of the CD36 gene. We identiﬁed two AP-2 binding sites in the
proximal promoter region of human CD36 gene, and conﬁrmed
that AP-2b could directly bind to CD36 promoter and enhance its
transcription. This induction is important for cholesterol uptake
and lipid accumulation in macrophages, as well as accelerated
foam cell formation.2. Materials and methods
2.1. Plasmids and oligonucleotides
Human AP-2b expression vectors: pEGFP-C1-AP-2b, pCMV-
Myc-AP-2b and pGEX-4T-2-AP-2b were gifted from Professor Jian
Zhang (College of Life Sciences, Hunan Normal University).
To perform luciferase assays, luciferase vector WpCD36-Luc
was constructed from pTAL-Luc using human CD36 promoter re-
gion (nt 409 to 184) ampliﬁed with PCR primers HCD36F and
HCD36R. Two potential AP-2 binding sites AP-2(U) and AP-2(D)lsevier B.V. All rights reserved.
Table 1
Oligonucleotides used in this article.
Name Sequence (50–30) Purpose Accession number (Genbank)
WtAP-2(U) TTCTGGCCTCTGACTTACTTG EMSA BD290672
WtAP-2(D) TCAATTCCTCTGGCAACAAAC EMSA BD290672
MtAP-2(U) TTCTGtCaTCTtAaTTACTTG Mutagenesis/EMSA BD290672
MtAP-2(D) TCAATTaaTCTtGaAACAAAC Mutagenesis/EMSA BD290672
HMT GATCGAACGGACCGCCCGCGGCCCGT EMSA Ref. [7]
NAP-2 ACTGCAGTGTAGGACTTTCCT EMSA Ref. [7]
HCD36F AGTTTCGCAAGCTCAGTC Luciferase BD290672
HCD36R TAGTGTCACCTCCCGTCA Luciferase BD290672
A (forward) CAAATCAGTTCCGTTGGTTC ChIP NT_165760.2
A (reverse) GAACAATATTTTAATACTATCCAGC ChIP NT_165760.2
B (forward) CCTTCAATCACGGTCCAC ChIP NT_165760.2
B (reverse) CCTTCCCTGCTATACTTTC ChIP NT_165760.2
RT-AP2F GCCGTGTCCGAGTATTTGA RT-PCR NM_009334
RT-AP2R CCTCCTTGTCGCCAGTTTT RT-PCR NM_009334
RT-CD36F CAAGCTATTGCGACATGATTAA RT-PCR NM_007643
RT-CD36R TGGATTCTGGAGGGGTGA RT-PCR NM_007643
SiRNA CTACTCAGTTCAACTTCAAAGTACA RNA interfering Ref. [2]
Scrambled control CTACTCAGccCAACggCAAAGTACA RNA interfering Ref. [2]
The consensus sequences of potential AP-2 binding sites are underlined. The mutated nucleotides are differentiated by lower case.
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in the proximal promoter region of CD36 gene (Fig. 3A) were
mutated, respectively, as described previously [7], primers MtAP-
2(U) and MtAP-2(D) were used; PCR products was sub-cloned into
pTAL-Luc vector upstream of luciferase gene at Kpn I/Hind III sites
to result in UMpCD36-Luc, DMpCD36-Luc and BMpCD36-Luc
constructs. Luciferase control vector pLuc-con was constructed
by Kpn I/Hind III digestion and self-ligation. All constructs were
conﬁrmed by DNA sequencing. Sequences of the primers are
shown in Table 1.
To knock down AP-2b, small interfering (si) RNA against the
mouse AP-2b and the scramble control were designed as described
previously [2] (see Table 1), and obtained from Invitrogen (the
scrambled control was designed with four base mutations). Sense
and antisense DNA oligonucleotides were inserted into the piGENE
mU6 vector. Five micrograms of either expression vector of siRNA
against AP-2b or scrambled control vector were used for
transfection.
2.2. oxLDL preparation
Human plasma lipoproteins were separated using sodium bro-
mide stepwise density gradient centrifugation [8]. oxLDL was pre-
pared as described previously [9]. Fluorescent labeled oxLDL (DiI-
oxLDL) was obtained from Intracel.
2.3. Cell culture and transient transfection
Raw 264.7 cells (ATCC TIB-71™) were cultured in 10% fetal calf
serum/DMEM (Gibco) supplemented with penicillin/streptomycin,
and transfected using NanoJuice™ (Merck) according to manufac-
turer’s instructions. The transfection efﬁciency is about 60%.
2.4. RNA extraction and quantitative real-time RT-PCR
Total RNA was extracted using the TRIzol reagent (Invitrogen).
One microgram of total RNA was subjected to a reverse transcrip-
tion step using the Promega reagents. Real-time PCR quantiﬁcation
was then performed using SYBR GREEN PCR Master Mix (Qigen).
b-Actin was used for normalization. AP-2b forward and reverse
primers were RT-AP2F and RT-AP2R; CD36 forward and reverse
primers were RT-CD36F and RT-CD36R (see Table 1). The above
primer sequences are highly conserved between human and
mouse.
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Western blot was carried out according to a previous publica-
tion [10] with AP-2b mouse monoclonal antibody (Santa Cruz)
and CD36 mouse monoclonal antibody (Chemicon). Protein bands
were detected by chemiluminescence.
2.6. High performance liquid chromatography (HPLC) analysis
Transfected cells were incubated with 50 mg/l of oxLDL for 36 h.
Then the cholesterol levels within cells were measured by HPLC as
described previously [11].
2.7. Luciferase assays
Expression vector pCMV-Myc-AP-2b was co-transfected with
pLuc-con, WpCD36-Luc, UMpCD36-Luc, DMpCD36-Luc or
BMpCD36-Luc, respectively. 36 h after transfection, luciferase as-
say was performed as described previously [12].
2.8. Electrophoretic mobility shift assay (EMSA)
WtAP-2(U) and WtAP-2(D) contain potential consensus AP-2
binding sites of human CD36 promoter region and their mutations
are named MtAP-2(U) and MtAP-2(D), respectively. Oligonucleo-
tides corresponding to AP-2 binding sites of human metallothio-
nein IIa promoter (HMT) were used as speciﬁc competitor,
unrelated oligonucleotides (NAP-2) were used as non-speciﬁc
competitor (sequences refer to [7]). The forward oligonucleotides
were end-labeled with [c-32P] ATP. The fusion protein GST-AP-2b
was used for binding and pull-down. EMSA was performed as de-
scribed previously [12]. The sequences of oligonucleotides used
in this study are shown in Table 1.
2.9. Chromatin immunoprecipitation (ChIP) assay
Cell lysates from 1.5  107 of Raw 264.7 cells and 2 lg of AP-2b
rabbit polyclonal antibody (Santa Cruz) were applied for ChIP assay
using chromatin immunoprecipitation kit (EZ ChIP™, Upstate).
Actin mouse monoclonal antibody (Wuhan Boster Biological Tech-
nology, Ltd.) was used as a control. Immunoprecipitated DNA was
then ampliﬁed using primers A (sense and antisense, see Table 1),
which produce a 593 bp fragment covering the potential AP-2
CT
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Fig. 2. Effects of AP-2b on CD36 expression. AP-2b overexpression vectors, siRNA
for AP-2b and corresponding control were transfected, respectively, into Raw 264.7
cells, 36 h later, mRNA and protein expression levels of AP-2b and CD36 were
detected (1, AP-2b siRNA; 2, scrambled siRNA; 3, untreated; 4, empty vectors; 5, AP-
2b overexpression). (A) Quantitative real-time RT-PCR analysis. Bars represent
mean ± S.D.; *P < 0.01 vs group 2, #P < 0.01 vs group 4; data from triplicated samples
of three independent experiments. (B) Western blot analysis.
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antisense, see Table 1) at about 3000 bp upstream from the prim-
ers A was used as control, which produce a 568 bp fragment. Equal
amounts (1 ng) of ChIP and input DNA were used for real-time PCR
analysis.
2.10. Statistic analysis
Data are presented as mean ± S.D. Differences were analyzed
by ANOVA. P < 0.05 or P < 0.01 was considered statistically
signiﬁcant.
3. Results and discussion
The development of foam cells containing massive amounts of
cholesteryl esters is a hallmark of atherosclerosis. To determine
whether AP-2b induces lipid accumulation and macrophage-de-
rived foam cell formation, we examined effects of AP-2b on the
oxLDL induced lipid accumulation. As the very low transfection
efﬁciency in human-derived macrophages, and the highly con-
served AP-2b protein between human and mouse, we performed
transfection studies in mouse-derived macrophages, Raw 264.7
cells. As shown in Fig. 1A and B, over-expression of AP-2b resulted
in an increased uptake of DiI-oxLDL in Raw 264.7 cells, whereas
siRNA against AP-2b leaded to a markedly decreasing of DiI-oxLDL
uptake (P < 0.01). To further quantify the intracellular lipids, we
quantitatively detect the levels of cholesterol and cholesterylFig. 1. Effects of AP-2b on oxLDL uptake. AP-2b overexpression vectors, siRNA for
AP-2b and corresponding control were transfected, respectively, into Raw 264.7
cells. At 6 h after transfection, 50 mg/l DiI-oxLDL or 50 mg/l oxLDL was added into
the culture medium (a, untreated; b, empty vectors; c, scrambled siRNA; d, AP-2b
overexpression; e, AP-2b siRNA). (A) The uptake of DiI-oxLDL was observed under a
ﬂuorescent microscope, and the quantitative image analysis was performed with
computer assisted pathological image analysis system (magniﬁcation 10, *P < 0.01
vs group b, #P < 0.01 vs group c). (B) Fluorescent observation found that AP-2b
positive cells accumulated more DiI-oxLDL (magniﬁcation 100, scale bar = 50 lm).
(C) The intracellular cholesterol levels were measured by HPLC (*P < 0.01 vs group b,
#P < 0.05 vs group c).
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Aesters. HPLC analysis showed that AP-2b overexpression increased
the cholesterol levels, especially the cholesteryl ester (CE) levels;
AP-2b siRNA signiﬁcantly decreased total cholesterol (TC) and free
cholesterol (FC) levels (Fig. 1C). Our results show that AP-2b can
promote lipid accumulation and foam cell formation. These
ﬁndings are consistent with another recent report in which over-
expression of AP-2b leads to lipid accumulation in 3T3-L1
adipocytes, too [2].
CD36 is the most important scavenger receptor which uptakes
oxLDL and contributes to the formation of foam cells. So, to dem-
onstrate whether AP-2b accelerates lipid accumulation and foam
cell formation through CD36, the CD36 transcripts were detected
using real-time RT-PCR. The mRNA level of CD36 was markedly
elevated by overexpression of AP-2b (P < 0.01 vs empty vector,
Fig. 2A), and suppressed by AP-2b siRNA compared to the scram-
bled siRNA (P < 0.01, Fig. 2A). Western blot analysis also indicated
the similar effects of AP-2b on CD36 protein level (Fig. 2B). The re-
sults demonstrate that the expression of CD36 is upregulated by
AP-2b at both mRNA and protein level. Together with the results
from Fig. 1, these ﬁndings suggest that AP-2b can accelerate lipid
accumulation, probably by stimulating the CD36 expression, and
consequently promoting foam cell formation. In addition, we also
found that AP-2a, another member of AP-2 family, promoted lipid
accumulation through upregulating CD36 in rat vascular smooth
muscle cells (VSMCs) (data not published).
Does AP-2b directly regulate CD36 expression? To answer this
question, we ﬁrst analyzed the proximal promoter region of human
CD36 gene using software Jarspar 2005 (Fig. 3A). There are two po-
tential AP-2 binding sites [GCCTCTGAC, denoted as AP-2(U) and
TCCTCTGGC, denoted as AP-2(D)] at 270-bp and 117-bp upstream
of human CD36 transcription starting site, respectively. We ana-
lyzed the CD36 promoter sequences in human, mouse, and rat
using software DNAstar, we found a highly conserved region in
CD36 promoter sequences, especially the completely consistent
AP-2(U) binding sites among these three species (Fig. 3B). It is very
interesting that there is a repeated A sequences about 14–16 A
bases at the downstream of the highly conserved AP-2(U) sites.
Then, a 593-bp of genomic fragment containing the two potential
AP-2 binding sites spanning 409-bp upstream of the transcription
starting site and 184-bp downstream of the transcription starting
site was cloned and inserted into the pTAL luciferase reporter
vector, resulting in a construct WpCD36-Luc. After co-transfection
of WpCD36-Luc and pCMV-myc-AP-2b into Raw 264.7 cells,
luciferase activities were determined. As shown in Fig. 3C, AP-2b
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Fig. 4. Identiﬁcation of AP-2 binding sites in CD36 promoter. (A) pCMV-Myc-AP-2b
was co-transfected with WpCD36-Luc, UMpCD36-Luc, DMpCD36-Luc and
BMpCD36-Luc, respectively. Oval represents wild-type AP-2 potential binding sites,
cross represents mutated sites. Luciferase activities were measured (relative
activity of luciferase shown was calculated from three experiments. Each value
was expressed as the percentage ratio of the luciferase activity to the control
WpCD36-Luc; the value of the control was set to 100%). (B) EMSA analysis. GST-AP-
2b was incubated with 32P-labeled oligonucleotides (indicated by asterisk); labeled
HMT was positive control, absence of AP-2b was negative control, 10- or 50-fold
unlabeled HMT and NAP-2 were speciﬁc or non-speciﬁc competitor, respectively;
Mt represents oligonucleotide with mutated AP-2 binding site, Wt represents
oligonucleotide with wild type AP-2 binding site.
Fig. 3. AP-2b binds to the promoter region of CD36. (A) The sequence of proximal
promoter region (nt from 409 to +184) of human CD36 gene. Potential AP-2
binding sites were boxed. Transcription starting site ‘‘G” is denoted as +1. (B)
Alignment with CD36 proximal promoter regions of the human, the mouse and the
rat. The red regions represent the completely conserved sequences, and the
potential AP-2(U) binding sites were boxed. (C) Raw 264.7 cells were transfected
with AP-2b expression vector pCMV-Myc-AP-2b together with reporter vector
WpCD36-Luc or its control pLuc-con. Luciferase activities were measured at 36 h
post-transfection. Data were presented as the mean ± S.D. from triplicated exper-
iments (*P < 0.01). (D) ChIP analysis by real-time PCR. (1) actin antibody and
primers A; (2) actin antibody and primers B; (3) no antibody and primers A; (4) no
antibody and primers B; (5) AP-2b antibody and primers A; (6) AP-2b antibody and
primers B. All real-time PCR ampliﬁcations were performed in triplicate. Results
normalized relative to input.
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of human CD36 gene (P < 0.01).
To further investigate whether endogenous AP-2b protein can
bind to CD36 gene promoter, we performed ChIP assay using AP-
2b antibody to immunoprecipitate DNA fragments which interacts
with transcription factor AP-2b. Fig. 3D showed that real-time PCR
ampliﬁcation detected the proximal promoter region containing
the potential AP-2 binding sites in CD36 promoter from AP-2b
immunoprecipitates. DNA of CD36 was fairly enriched by ChIP
with anti-AP-2b and ampliﬁcation with primers A (about 28%,
bar 5), whereas the ampliﬁcation of control region with primersB was at background level (bar 6). ChIP controls with anti-actin
or without antibody were at background level, too (bars 1–4). Thus,
speciﬁc ampliﬁcation was achieved by precipitation with anti-AP-
2b only. No signiﬁcant ampliﬁcation was detected in the absence of
antibody or in the presence of anti-actin antibody. This further
supports the luciferase assay results, and conﬁrms that AP-2b di-
rectly binds to the promoter of CD36 gene in vivo. We also found
that endogenous AP-2a protein could bind to CD36 gene promoter
in rat VSMCs and U937 cells in another study (data not published).
To ﬁgure out the signiﬁcance of AP-2(U) and AP-2(D) binding
sites in regulating CD36 transcription, we generated reporter con-
structs with mutations on these two sites: UMpCD36-Luc [muta-
tion for AP-2(U)], DMpCD36-Luc [mutation for AP-2(D)] and
BMpCD36-Luc (double mutations for these two sites). Luciferase
assays were performed at 36 h after co-transfection of pCMV-
myc-AP-2b and reporter constructs. The transcription activities of
CD36 gene signiﬁcantly decreased when either of the two AP-2
binding sites was mutated. Mutation of AP-2(D) resulted in more
signiﬁcant decrease than mutation of AP-2(U) (Fig. 4A). Moreover,
we performed EMSA to conﬁrm the binding of AP-2b into these
two sites. Wild-type oligonucleotide probes WtAP-2(D)* and
WtAP-2(U)* successfully formed DNA-protein complexes with
AP-2b (Fig. 4B, lanes 2 and 11). These bindings were inhibited by
unlabeled speciﬁc competitor oligonucleotide HMT (Fig. 4B, lanes
3, 4 and 12, 13), but not affected by unlabeled non-speciﬁc compet-
itor oligonucleotide NAP-2 (Fig. 4B, lanes 7, 8 and 16, 17). However,
mutated oligonucleotide probes MtAP-2(D)* and MtAP-2(U)* did
not form DNA-protein complexes at all (Fig. 4B, lanes 1 and 10).
The speciﬁc competitor HMT competed out dose-dependently the
AP-2(D) site but not AP-2(U) site, it was consistent with the result
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Ain Fig. 4A, mutation of AP-2(D) site resulted in more signiﬁcant de-
crease in CD36 gene transcription activity than mutation of AP-
2(U) site. It revealed that binding of AP-2b to AP-2(D) was stronger
than AP-2(U) under our experiment conditions. Our results indi-
cate that the binding sites of AP-2b in the promoter region of
CD36 gene are GCCTCTGAC and TCCTCTGGC, only with minor var-
iation from the previous reported consensus sequence: GCC N3/4
GGC[13]. Taken together, these results suggest that AP-2b upregu-
lates the expression of CD36 through directly binding to its pro-
moter and activating its transcription.
There are other proofs supporting our conclusion that AP-2 con-
tributes to the formation of foam cells. Ikeda et al. demonstrated
overexpression of AP-2b in 3T3-L1 adipocytes decreased expres-
sion and secretion of adiponectin by inhibiting the promoter tran-
scription activity of adiponectin gene [14]; Adiponectin, the
adipocyte-derived plasma protein, is decreased in patients with
coronary artery disease and suppresses macrophage-to-foam cell
transformation by reducing the class A scavenger receptor (SRA)
promoter activity [15]. Furthermore, Iwamoto et al. conﬁrmed that
AP-2a negatively regulated the ABCA1 gene transcription by di-
rectly binding to the promoter of ABCA1 gene [16,17]; ABCA1 is
a rate limiting factor of HDL biogenesis, thereby is a key factor
for modulating the cholesterol efﬂuence in atherosclerosis; Over-
expression of ABCA1 in mice exhibited an increase of HDL and
reduction of atherosclerosis [18,19]. Therefore, we propose a new
mechanism that AP-2 may contribute to the formation of foam
cells from two directions. On one hand, AP-2 increase the choles-
terol uptake through upregulating CD36 expression, and downreg-
ulating adiponectin expression, respectively; on the other hand,
AP-2 decrease the cholesterol efﬂuence through downregulating
ABCA1 expression. Furthermore, AP-2 family has been found to di-
rectly regulate vascular endothelial growth factor [20], apolipopro-
tein E [21] and tryptase [22]. All these genes have been shown to
be closely involved in atherosclerotic development, therefore we
hypothesize that AP-2 may participate in atherogenesis, it is wor-
thy of further investigation on this regard.
In summary, our study here demonstrates nuclear transcription
factor AP-2b protein directly binds to the promoter region of CD36
gene to enhance its transcription, and then contributes to lipid
accumulation and foam cell formation in macrophages. So, inter-
vention of AP-2b probably can reduce cholesterol uptake, block
accumulation of lipid and development of foam cell formation,
and subsequently suppress atherogenesis.
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